DigiBiomics
DigiBiomics builds an AI-driven multimodal diagnostics platform for lung disease, cancer, and mental health. It serves healthcare organizations, biotech and pharmaceutical companies, and academic research institutions through four proprietary products (LungSense, PulmoDeep, TheraPredict, Cancer Care) plus data and AI model services.
- Company typePrivate
- Founded2021
- HeadquartersMississauga, Canada
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What DigiBiomics does
DigiBiomics Inc. is a Canadian-headquartered AI health technology company building a multimodal data fusion platform for precision diagnostics. Its product portfolio comprises four proprietary platforms — LungSense (point-of-care respiratory screening using cough and breathing acoustics plus imaging), PulmoDeep (lung disease detection for pneumonia, tuberculosis, and lung cancer), TheraPredict (EEG-based functional connectivity biomarker platform for antidepressant selection in major depressive disorder), and Cancer Care (multimodal precision oncology across colon, head and neck, esophageal, glioblastoma, and breast cancers). The underlying technology combines medical imaging, genomics, EEG-derived biomarkers, audio signal analysis, and structured clinical and demographic data into integrated diagnostic pipelines.
The company monetizes through four service lines: AI Model-as-a-Service (custom ML model development, deployment, and monitoring on a recurring basis), Clinical Data-as-a-Service (secure real-world clinical data access for healthcare, biotech, and pharma), End-to-End Workflow Automation (professional services for digital transformation of healthcare systems), and Collaboration and Training (joint R&D and digital literacy programs with academic and healthtech partners). Go-to-market relies on enterprise field sales, inbound website conversion, and conference- and community-led engagement (University of Oxford, King AbdulAziz University, University of Toronto, Jawaharlal Nehru University, SLB Neutrophil Conference), targeting healthcare provider organizations, biotech and pharmaceutical companies, and academic research institutions.
DigiBiomics is privately held, founded by Dr. Meraj A. Khan (Clinical Research Scientist, Co-Founder), with a Mississauga, Ontario headquarters and a Dubai regional office. Headcount is 11–50, the company is currently raising a $1M seed round (2026), and it has received the SickKids Sass-Kortsak Award (2024) in recognition of research contributions by its co-founder. Pricing is not publicly disclosed and no enterprise customer logos are available in source materials, indicating an early commercialization phase.
DigiBiomics firmographics
Firmographics- Name
- DigiBiomics
- Legal name
- DigiBiomics Inc.
- Website
- https://digibiomics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DigiBiomics builds an AI-driven multimodal diagnostics platform for lung disease, cancer, and mental health. It serves healthcare organizations, biotech and pharmaceutical companies, and academic research institutions through four proprietary products (LungSense, PulmoDeep, TheraPredict, Cancer Care) plus data and AI model services.
- Ownership category
- akta.pro rank
DigiBiomics industry classification
Industry- Product category
- Healthcare AI Diagnostics and Precision Medicine Software
- NAICS
- Medical Laboratories (621511), Software Publishers (5132)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Diagnostic & Triage Decision Support (HLACAGAA), Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ)
Keywords
Where DigiBiomics is headquartered
LocationHeadquarters
- HQ city
- Mississauga
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
DigiBiomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- AI Model as a Service (MaaS): DigiBiomics develops and deploys customized ML and AI models for healthcare organizations, providing evidence-based precision diagnoses and treatment plans. Revenue is generated through model development, integration, monitoring, and validation services, likely on a project or subscription basis.
- Clinical Data as a Service (DaaS): Providing secure, scalable access to real-world clinical data for healthcare organizations, biotech, and pharmaceutical companies. Revenue is generated through data access fees, compliance services, and on-demand analytics, potentially billed on a usage or subscription basis.
- End-to-End Workflow Automation Services: Digital transformation services for healthcare systems, including automated data capture, AI-powered decision support, customizable workflow design, and end-to-end monitoring. Revenue is generated through professional services and implementation engagements.
- Collaboration & Training Services: Partnering with academic institutions, healthcare, and healthtech organizations for AI adoption and digital literacy training. Revenue generated through training programs, joint R&D programs, and mentorship engagements.
Go-to-market motion4 records
Distribution channels2 records
Marketing channels6 records
DigiBiomics product offering
Product offeringCore offering
DigiBiomics develops and sells AI-powered precision diagnostic platforms that analyze multimodal medical data (imaging, genomics, clinical records, EEG, audio/cough sounds, demographics) for early detection of lung disease, cancer, and mental health conditions. Its product portfolio includes LungSense, PulmoDeep, TheraPredict, and Cancer Care, complemented by AI Model as a Service, Clinical Data as a Service, and workflow automation services sold to healthcare providers, biotech firms, and pharmaceutical companies.
Product overview
DigiBiomics offers an integrated AI-powered diagnostic platform portfolio focused on precision medicine. The core offerings include LungSense (respiratory health monitoring via cough/breathing analysis and imaging), PulmoDeep (lung disease diagnostic platform), TheraPredict (mental health/ antidepressant therapy prediction using EEG), and Cancer Care (precision oncology). Supporting services include AI Model as a Service (custom ML model development), Clinical Data as a Service (real-world clinical data access), End-to-End Workflow Automation, and Collaboration & Training programs. The platform emphasizes multimodal data integration combining imaging, audio, genomics, and clinical data for early disease detection and personalized treatment.
Differentiator
Problem solved
Functional benefit
Brands
- LungSense: AI-powered respiratory screening and monitoring platform that analyzes cough sounds, clinical symptoms, and medical imaging to detect early signs of lung disease including COPD, tuberculosis, pneumonia, and asthma.
- PulmoDeep
- TheraPredict
- Cancer Care
Products and services
- LungSense AI-powered respiratory screening and monitoring platform that analyzes cough sounds, breathing acoustics, clinical symptoms, and medical imaging to detect early signs of COPD, tuberculosis, pneumonia, asthma, and cardiac sounds, delivering instant respiratory risk scores at the point of care for clinicians and care teams.
- PulmoDeep AI-powered diagnostic platform that detects lung diseases including pneumonia, tuberculosis, and lung cancer by analyzing medical images and patient data, providing accurate early detection and timely triage recommendations for clinicians and healthcare organizations.
- TheraPredict AI-driven platform for diagnosis of major depressive disorder and prediction of antidepressant therapy response, leveraging EEG-based functional connectivity data alongside clinical, demographic, and genetic information to deliver biomarker-based diagnosis and personalized treatment recommendations for clinicians and mental health providers.
- Cancer Care Precision oncology platform integrating histopathological imaging, genomics, and clinical information for early, accurate diagnosis and personalized treatment recommendations for colon, head and neck, esophageal, glioblastoma, and breast cancers, targeted at oncologists and cancer care teams.
- AI Model as a Service (MaaS) Customized machine learning and AI model development service delivering evidence-based precision diagnoses and treatment plans, including pre-trained disease-specific models, clinical workflow integration, ongoing model monitoring, and scalability validation for healthcare organizations, biotech, and pharmaceutical companies.
- Clinical Data as a Service (DaaS) Secure, large-scale access to anonymized real-world clinical data for healthcare organizations, biotech firms, and pharmaceutical companies, supporting research, drug development, and digital health solution validation with compliance and on-demand analytics.
- End-to-End Workflow Automation Digital transformation service for healthcare systems covering automated data capture, AI-powered decision support, customizable workflow design, and end-to-end monitoring and reporting to streamline clinical workflows.
- Collaboration and Training Partnership programs with academic institutions, healthcare, and healthtech organizations to promote AI adoption and digital literacy, including joint R&D, knowledge sharing, expert training, and mentorship engagements.
Quantifiable outcome
- LungSense delivers respiratory risk score instantly at point of care with no labs, no specialists, no delays
- +4 more outcomes
Companies that use DigiBiomics
Customer profileSegments3 records
Ideal customer profiles3 records
DigiBiomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature6 records
DigiBiomics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Carelick Business NetworkminorDigiBiomics partnered with Carelick Business Network, a local community organization, to organize an educational open house seminar focused on healthcare digitalization careers. The seminar aimed to inspire and inform young professionals and students about careers in healthcare digitalization, demonstrating DigiBiomics' commitment to community engagement and AI adoption in healthcare.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
DigiBiomics competitors and assessment
Company assessmentDirect peers
- Qure.ai: AI-driven medical imaging diagnostics company specializing in chest X-ray and head CT interpretation for lung disease, tuberculosis, and stroke — directly competing with DigiBiomics' PulmoDeep and LungSense in the AI lung diagnostics space.
- Aidoc: AI-powered medical imaging platform offering triage and workflow solutions for radiology departments across multiple specialties — comparable to DigiBiomics' imaging-based diagnostic portfolio and enterprise hospital GTM motion.
- PathAI: AI-driven pathology platform for cancer diagnosis and biomarker discovery using histopathological imaging and clinical data — directly comparable to DigiBiomics' Cancer Care Platform integrating histopathology, genomics, and clinical information.
- Owkin: AI biotech company using multimodal patient data (imaging, genomics, clinical) for precision medicine and drug discovery, with pharma/biotech data partnerships — comparable business model and multimodal AI approach to DigiBiomics' DaaS/MaaS offerings.
- Zebra Medical Vision (Nanox.AI): AI medical imaging analytics company offering multi-organ diagnostic algorithms (including lung) integrated into radiology workflows — direct competitor to DigiBiomics' lung imaging diagnostics with similar GTM into healthcare enterprises.
- ResApp Health: Digital health company developing AI-based respiratory diagnostics using cough sound analysis via smartphone — the closest direct competitor to DigiBiomics' LungSense cough-acoustics approach for point-of-care lung disease screening.
- Arterys: Cloud-native AI medical imaging platform with FDA-cleared diagnostic models across multiple specialties — comparable enterprise imaging AI platform targeting hospitals with workflow integration similar to DigiBiomics' PulmoDeep/Cancer Care vision.
- Paige.AI: AI company focused on computational pathology for cancer diagnosis, integrating imaging with clinical and molecular data — directly comparable to DigiBiomics' Cancer Care Platform across oncology precision diagnostics.
Broad incumbents
- Tempus Labs: Large precision medicine company combining multimodal data (imaging, genomics, clinical records) with AI for oncology and other disease areas, plus a data-as-a-service offering to pharma/biotech — overlaps with DigiBiomics' MaaS, DaaS, and Cancer Care strategy at a much larger scale.
Emerging players
- CureMetrix: AI-based medical imaging company for women's health and oncology diagnostics — adjacent peer sharing DigiBiomics' AI imaging diagnostics model with a narrower but clinically validated focus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
DigiBiomics social profiles
Digital presenceDigiBiomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
DigiBiomics leadership team
Management profileNumber of profiles
Profiles10 records
DigiBiomics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DigiBiomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DigiBiomics
What does DigiBiomics do?
DigiBiomics develops and sells AI-powered precision diagnostic platforms that analyze multimodal medical data (imaging, genomics, clinical records, EEG, audio/cough sounds, demographics) for early detection of lung disease, cancer, and mental health conditions. Its product portfolio includes LungSense, PulmoDeep, TheraPredict, and Cancer Care, complemented by AI Model as a Service, Clinical Data as a Service, and workflow automation services sold to healthcare providers, biotech firms, and pharmaceutical companies.
Is DigiBiomics a public or private company?
DigiBiomics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DigiBiomics founded?
DigiBiomics was founded in 2021. It employs 11 to 50 people.
Where is DigiBiomics based?
DigiBiomics is headquartered in Mississauga, Canada, in the North America region.
How does DigiBiomics make money?
Four revenue lines are on record. AI Model as a Service (MaaS) is the primary driver. The others are clinical Data as a Service (DaaS), end-to-End Workflow Automation Services and collaboration & Training Services.
Who are DigiBiomics's main competitors?
Direct peers on record are Qure.ai, Aidoc, PathAI, Owkin, Zebra Medical Vision (Nanox.AI), ResApp Health, Arterys and Paige.AI. Tempus Labs is listed as a broad incumbent. CureMetrix is listed as an emerging player.
Does DigiBiomics have an API?
No public API is recorded for DigiBiomics.
What industry is DigiBiomics in?
DigiBiomics's product category is Healthcare AI Diagnostics and Precision Medicine Software. Its primary akta.pro industry code is HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 621511 and its SIC code is 2835.